The pharmaceutical manufacturer Sandoz is leading what it says will be a global effort to increase the adoption of biosimilar drugs and ensure patients can access them at an affordable price, with the goal of ultimately creating cost savings for the entire health care system. Sandoz, a division of pharmaceutical company Novartis, launched an initiative called Act4Biosimilars with the goal of increasing global adoption of biosimilar medicines by at least 30%, in 30 or more countries, by 2030. It is...